Stocks · News reference

HC Wainwright & Co. Maintains Buy on AEON Biopharma, Lowers Price Target to $1.2

Aug 14, 2026, 5:32 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Douglas Tsao maintains AEON Biopharma (AMEX:AEON) with a Buy and lowers the price target from $5 to $1.2.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 14, 2026, 5:32 PM
Checked: Aug 14, 2026, 5:32 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 10, 2026, 11:43 AMBenzinga Newsdesk
AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.
AEON
BenzingaSep 10, 2026, 8:34 AMAvi Kapoor
Why AeroVironment Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
AeroVironment surged 5.8% premarket after beating Q1 revenue and EPS estimates; Synergy CHC led gainers, while Ribbon Acquisition fell.
AEO AEON AVAV CLIK COO
BenzingaSep 9, 2026, 12:03 PMBenzinga Newsdesk
AEON Biopharma Says Pilot Forced Degradation Study Showed ABP-450 And AbbVie's BOTOX Lost Potency At Comparable Rates Under Thermal Stress, Similar Methionine Oxidation Patterns; Plans Multi-Lot Comparability Study In H1 2027
AEON
BenzingaAug 24, 2026, 12:05 PMBenzinga Newsdesk
AEON Biopharma Designates Paul Lee As Chief Regulatory Office
AEON